<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094859</url>
  </required_header>
  <id_info>
    <org_study_id>2012-05</org_study_id>
    <nct_id>NCT02094859</nct_id>
  </id_info>
  <brief_title>GlucoClearTM System ICU Study</brief_title>
  <official_title>GlucoClearTM System ICU Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>95 bis boulevard Pereire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>75017 Paris - France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this Study is evaluation of the safety and performance of the&#xD;
      GlucoClear System (System).&#xD;
&#xD;
      The primary safety objective will be assessed by:&#xD;
&#xD;
      • Evaluation of any serious adverse device effects upon Sensor insertion through Sensor&#xD;
      removal and a follow-up assessment one week (7 ± 3 days) after Sensor removal.&#xD;
&#xD;
      The primary performance objective will be evaluated using the following criteria:&#xD;
&#xD;
      15/20% Performance: Blood glucose measurements from the System must meet the ISO 15197 15/20%&#xD;
      accuracy criteria (at least 95% of the matched pairs within ± 15 mg/dL of Comparator values ≤&#xD;
      75 mg/dL and within ±20% of Comparator values &gt; 75 mg/dL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Non-randomized, non-treatment, prospective, open label Study.&#xD;
&#xD;
      After providing written informed consent, subjects meeting Inclusion/Exclusion Criteria will&#xD;
      be connected to the System for a maximum of 72 hours.&#xD;
&#xD;
      For the purposes of this clinical Study, the System will not display real-time glucose&#xD;
      values, glucose trend graphs, or glucose alarms to either the Study Subjects or the Study&#xD;
      Site Personnel. There will be no treatment of any Subject based on the output of the System.&#xD;
      Diabetes management decisions throughout this Study (if applicable) will be conducted&#xD;
      according to hospital procedures.&#xD;
&#xD;
        -  1 set of laboratory measurements will be drawn per Subject for baseline.&#xD;
&#xD;
        -  A maximum of 82 blood samples will be drawn per Subject during the 72 hour monitoring&#xD;
           session including.&#xD;
&#xD;
             -  Up to 75 blood samples drawn for comparative glucose measurement on laboratory&#xD;
                analyzers. Blood samples will be taken from the sampling catheter in the peripheral&#xD;
                vein in the contralateral extremity (relative to placement of the System) with no&#xD;
                more than 25 samples taken within one day (00:00 to 23:59) for glucose measurement&#xD;
                on laboratory analyzers (e.g., Yellow Springs Instrument glucose analyzer (YSI),&#xD;
                Radiometer blood analyzer);&#xD;
&#xD;
             -  Up to three (3) sets of laboratory measurements; and&#xD;
&#xD;
             -  Up to 4 other blood samples, as needed. One week (7 + 3 days) after Sensor removal,&#xD;
                subjects will be contacted for a follow-up assessment and document any subsequent&#xD;
                adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>15/20% Performance</measure>
    <time_frame>During 72 hours of anticipated Sensor dwell time</time_frame>
    <description>15/20% Performance: Blood glucose measurements from the System must meet the ISO 15197 15/20% accuracy criteria (at least 95% of the matched pairs within ± 15 mg/dL of Comparator values ≤ 75 mg/dL and within ±20% of Comparator values &gt; 75 mg/dL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12/12.5% Performance</measure>
    <time_frame>During 72 hours of anticipated Sensor dwell time</time_frame>
    <description>12/12.5% Performance: Propor-tion of matched pairs meeting within ± 12 mg/dL for Compara-tor values ≤ 100 mg/dL and within ± 12.5% for Comparator values &gt; 100 mg/dL.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Accurate Blood Glucose Monitoring in Critical Care Setting</condition>
  <arm_group>
    <arm_group_label>GlucoClear System</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with an anticipated ICU stay of at least 24 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  ICU ≥ 24 hours&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transplant patient&#xD;
&#xD;
          -  Brain injury/surgery patient&#xD;
&#xD;
          -  End stage medical conditions or diseases&#xD;
&#xD;
          -  Restricted venous access&#xD;
&#xD;
          -  History of HIT&#xD;
&#xD;
          -  Contraindication for anti-coagulation or bleeding disorder&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  In other drug, device, or biologic study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Foubert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze-Lieve-Vrouwziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <last_update_submitted>March 21, 2014</last_update_submitted>
  <last_update_submitted_qc>March 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Monitoring</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

